• Honorio T Benzon, Timothy P Maus, Hye-Ryun Kang, David A Provenzano, Anuj Bhatia, Felix Diehn, Ariana Nelson, Zachary L McCormick, Benjamin P Liu, Javier de Andres Ares, Magdalena Anitescu, Kristine Blackham, Arun Bhaskar, Silviu Brill, Jeremy Collins, Ashish Gulve, Robert W Hurley, Young Hoon Jeon, Jee Youn Moon, Richard L Rauck, Meghan Rodes, Ryan K Lee, Vinil Shah, Harsha Shanthanna, Jan van Zundert, Marc Huntoon, James P Rathmell, Mario Sanchez Borges, Steven P Cohen, and Paul A Greenberger.
• From the Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
• Anesth. Analg. 2021 Aug 1; 133 (2): 535-552.

AbstractThis Practice Advisory presents a comprehensive and evidence-based set of position statements and recommendations for the use of contrast media in interventional pain procedures. The advisory was established by an international panel of experts under the auspices of 11 multinational and multispecialty organizations based on a comprehensive review of the literature up to December 31, 2019. The advisory discusses the risks of using gadolinium-based contrast agents. These include nephrogenic systemic fibrosis, gadolinium brain deposition/retention, and encephalopathy and death after an unintentional intrathecal gadolinium injection. The advisory provides recommendations on the selection of a specific gadolinium-based contrast agent in patients with renal insufficiency, those who had multiple gadolinium-enhanced magnetic resonance imaging examinations, and in cases of paraspinal injections. Additionally, recommendations are made for patients who have a history of mild, moderate, or severe hypersensitivity reactions to contrast medium.Copyright © 2021 International Anesthesia Research Society.

25 keywords...

hide…